Tuberculous meningitis (TBM) is the most serious form of Mycobacterium tuberculosis infection, causing mortality and disability in more than half of the patients. Current standard treatment for TBM is based on those developed to treat pulmonary tuberculosis, which does not take into account the differential ability of anti-tuberculosis drugs to penetrate the brain. With both good central nervous system penetrance and anti-tuberculosis efficacy that have been demonstrated in drug-resistant tuberculosis, linezolid may be a promising antimicrobial in TBM treatment. The purpose of this study is to evaluate the effectiveness of linezolid in the treatment of TBM.
Study Type
OBSERVATIONAL
Enrollment
150
To add linezolid 600mg or 1200mg daily in the initial or subsequent treatment regimen of TBM.
Infectious department of Huashan Hospital, Fudan University
Shanghai, China
RECRUITINGSurvival
Time frame: 5 years
Number of participants with Medical Research Council grade deterioration
Time frame: From the beginning of anti-tuberculosis treatment to the first documented progression, assessed up to 5 years.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.